ArriVent BioPharma Business Summary

ArriVent BioPharma, Inc. (AVBP) is a clinical-stage biopharmaceutical company that operates through a business model focused on the identification, development, and eventual commercialization of differentiated oncology therapeutics. As of February 2026, the company remains pre-commercial, generating capital primarily through public equity offerings and strategic licensing agreements rather than product sales. Its primary business segments are centered on its lead development candidate, furmonertinib—an oral EGFR inhibitor targeting non-small cell lung cancer (NSCLC)—and an emerging pipeline of next-generation antibody-drug conjugates (ADCs), including ARR-217 for gastrointestinal tumors. In the competitive landscape, ArriVent contends with established oncology players such as Exelixis, Puma Biotechnology, and Legend Biotech, positioning itself as a specialized developer of precision medicines for underserved, mutation-driven cancer populations where it seeks to establish first-in-class or best-in-class clinical profiles. The company was co-founded by a veteran leadership team with a distinguished pedigree in the biopharmaceutical industry, many of whom previously led Viela Bio to a $3.1 billion acquisition. The executive team is headed by Chairman and CEO Zhengbin (Bing) Yao, PhD, formerly of MedImmune and AstraZeneca, alongside co-founders Stuart Lutzker, MD, PhD (President of R&D, ex-Genentech) and Robin LaChapelle (COO). Key technical operations are overseen by Chief Technology Officer Yang Wang, PhD, who brings extensive experience in CMC and process development from Viela Bio and MedImmune, while Brent S. Rice serves as Chief Commercial Officer. ArriVent is backed by a robust roster of notable investors, including Hillhouse Investment Management—which maintains a significant 9.5% stake—as well as Eli Lilly Investment Consulting, Sofinnova Investments, and institutional shareholders such as BlackRock and Vanguard.